Macular degeneration: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• VEGF 19
• NRF2 0
• GLP-1 0
• PPAR 0
• AKT 0
• JNK 0
• APOE 0
• PI3K 0
• SIRT1 0
• ALK 1
• AMPK 0
• MAPK 0
• mTOR 0
• GPX4 0
• JAK 0
• NLRP3 0
• TP53 0
• ERK 0
• PCSK9 0
• STAT3 0
• STING 0
• YAP 0
• BCL-2 0
• CTNNB1 0
• CXCR4 0
• HIF-1 0
• IL-6 0
• MMP-9 1
• PDGFR 0
• SGLT2 1
• TNF 0
• IL-17 0
• MDM2 0
• MYC 0
• NOTCH3 0
• PKM2 0
• RPGR 0
• SOD1 0
• TERT 0
• TFEB 0
• TREM2 0

24 of 1,019 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding retinal cell communication to counteract vision loss in aging (VisionGuard)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €263,393· until Apr 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Drusen Reconstitution in an Engineered AMD Model using Retinal Pigment Epithelium (DREAM_RPE)

  Universidade Nova de Lisboa· Lisboa, Portugal· EU contribution €207,183· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Doctoral network on discovering pathomechanisms and novel drug optimization for AMD (PANDORA)

  Eberhard Karls Universitaet Tuebingen· Tuebingen, Germany· EU contribution €4,020,973· until Sept 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Full field optoretinography for elderly eye health (FFORGE)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Lysophagy as a new strategy for neuroprotection in dry AMD (AMD_Prog)

  Universite de Fribourg· Fribourg, Switzerland· EU contribution €307,959· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing therapeutic base editing for vision loss (BaseVision)

  Institut fur Molekulare und Klinische Ophthalmologie Basel· Basel, Switzerland· EU contribution €2,000,000· until May 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  Cell-targeted Biophotonic Nanoparticles for Vision Restoration (NanoFlash)

  The Chancellor Masters and Scholars of the University of Cambridge· Cambridge, United Kingdom· EU contribution €2,999,978· until Apr 2030· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Visual Impairment Screening using Images from Ophthalmology and Novel pathways for Structural Analysis and Fast Evaluation (VISIONSAFE)

  Universidad de Zaragoza· Zaragoza, Spain· EU contribution €1,497,873· until Jan 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care (I-SCREEN)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €3,454,614· until Dec 2028· 8 countries

• European Commission (Horizon Europe) · HORIZON-EIC

  ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases

  Silk Biomed, S.l.· Galapagar, Spain· EU contribution €2,433,300· until Nov 2026· 4 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 12 running projects, newest first. Listed amounts together: €21.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06961370· Hoffmann-La Roche· Updated 4 Nov 2026

  “The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the protocol-defined stopping criteria.”Registry text, quoted unchanged. Source

• Withdrawn

  Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration

  NCT05780931· VA Office of Research and Development· Updated 5 Oct 2026

  “I was instructed to stop the study, because the underlying VA grant has run out of funds.”Registry text, quoted unchanged. Source

• Terminated

  Study of New Mutations in Cone Disorders

  NCT04658251· University Hospital, Lille· Updated 22 May 2026

  “End of COVID”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of the SING IMT in an Israeli Cohort

  NCT05941273· VisionCare, Inc.· Updated 18 May 2026

  “This decision is driven by the sponsor's strategic considerations.”Registry text, quoted unchanged. Source

• Terminated

  FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

  NCT03846193· Gyroscope Therapeutics Limited· Updated 28 Jan 2026

  “The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.”Registry text, quoted unchanged. Source

• Terminated

  HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04566445· Gyroscope Therapeutics Limited· Updated 28 Jan 2026

  “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.”Registry text, quoted unchanged. Source

• Terminated

  EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04437368· Gyroscope Therapeutics Limited· Updated 27 Jan 2026

  “Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

  NCT05893537· Cognition Therapeutics· Updated 16 Apr 2025

  “The trial was closed as part of a strategic business decision.”Registry text, quoted unchanged. Source

• Terminated

  Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study

  NCT05200624· Center for Eye Research Australia· Updated 15 Apr 2025

  “Difficulty with meeting recruitment targets”Registry text, quoted unchanged. Source

• Terminated

  Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

  NCT04764656· Novartis Pharmaceuticals· Updated 25 Mar 2025

  “The study was terminated earlier since the obtained sample was not representative of the Portuguese population, and pointed to the high fragility in evaluating the data, making it difficult to carry out a statistical study and draw valid conclusions.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Amgen· Source

• A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

  NCT06722157· Boehringer Ingelheim· Source

• Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

  NCT06018558· Ocugen· Source

• A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07441642· Novartis Pharmaceuticals· Source

• A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Hoffmann-La Roche· Source

• Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration

  NCT07084883· iHealthScreen Inc· Source

• A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Regeneron Pharmaceuticals· Source

• A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06635148· Janssen Research & Development, LLC· Source

• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

  NCT04853251· Genentech, Inc.· Source

• Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss

  NCT07216924· University of Minnesota· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 11
• Mendelian Randomization Analysis 26
• CRISPR-Cas Systems 7
• Gene Expression Profiling 16
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 16
• Mass Spectrometry 11
• Flow Cytometry 8
• Immunohistochemistry 15
• Liquid Biopsy 1
• Magnetic Resonance Imaging 6
• Machine Learning 14
• Deep Learning 31
• Cohort Studies 26
• Genome-Wide Association Study 24

• AAV Gene Augmentation Therapy Rescues the Phenotype in the RDH5-/- Cat Model of Fundus Albipunctatus.

  Invest Ophthalmol Vis Sci, Oct 2026

• Development of a Targeted Choroidal Injury Model for the Study of Retinal Degenerations and Therapeutic Cell Replacement.

  Transl Vis Sci Technol, Aug 2026

• From Subretinal to Intraretinal Fluid in Type 1 Macular Neovascularization: A Clinicopathologic Disease Transition Model.

  Invest Ophthalmol Vis Sci, Aug 2026

• Functional and Structural Characterization of a Large Animal Model of RDH5-Associated Retinopathy.

  Transl Vis Sci Technol, Aug 2026

• RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD.

  Invest Ophthalmol Vis Sci, May 2026

• Müller Cell Changes and Subretinal Membrane Formation in an Eye With Multifocal Geographic Atrophy.

  Invest Ophthalmol Vis Sci, Apr 2026

• Choroidal Vascular Findings in a Case of Multifocal Geographic Atrophy: A Clinicopathologic Correlation.

  Invest Ophthalmol Vis Sci, Mar 2026

• The effects of zinc supplementation on primary human retinal pigment epithelium.

  J Trace Elem Med Biol, Mar 2018

• Cone Viability Is Affected by Disruption of Melatonin Receptors Signaling.

  Invest Ophthalmol Vis Sci, Jan 2016

• Bis(zinc-dipicolylamine), Zn-DPA, a new marker for apoptosis.

  Invest Ophthalmol Vis Sci, Jul 2014

See which targets of this disease your abstract mentions, and go to the people working on them.